Photo taken from Allison Betof Warner/X
Jun 2, 2024, 09:37
Allison Betof Warner: Relativity-048 presented by Paolo A. Ascierto at ASCO24
Allison Betof Warner, Director of Melanoma Medical Oncology and Solid Tumor Cellular Therapy at Stanford Cancer Institute, recently posted on X:
“We’ve been waiting for this one!!
RELATIVITY-048 (ipilimumab 1Q8wi and nivolumab and relatimab) presented by Paolo A. Ascierto.
ORR 52% by BICR. Clinical benefit rate 76%. 50% discontinuation due to toxicity.
Responses in poor prognosis disease.
7/14 with liver metastasis and 2/3 with brain metastasis responded. More to come on brian mets with this combination!
Rate of G3/4 TRAE is a 39%…actually significantly better than full dose ipilimumab and nivolumab.”
Source: Allison Betof Warner/X
